VYNE Therapeutics Statistics
Share Statistics
VYNE Therapeutics has 15.21M
shares outstanding. The number of shares has increased by 4.69%
in one year.
Shares Outstanding | 15.21M |
Shares Change (YoY) | 4.69% |
Shares Change (QoQ) | 3.11% |
Owned by Institutions (%) | 0.09% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 2,198 |
FTD / Avg. Volume | 1.37% |
Short Selling Information
The latest short interest is 191.07K, so 1.3% of the outstanding
shares have been sold short.
Short Interest | 191.07K |
Short % of Shares Out | 1.3% |
Short % of Float | 1.31% |
Short Ratio (days to cover) | 1.47 |
Valuation Ratios
The PE ratio is -3.58 and the forward
PE ratio is -1.29.
VYNE Therapeutics's PEG ratio is
0.05.
PE Ratio | -3.58 |
Forward PE | -1.29 |
PS Ratio | 284.78 |
Forward PS | 1.5 |
PB Ratio | 2.74 |
P/FCF Ratio | -4.19 |
PEG Ratio | 0.05 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for VYNE Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.35,
with a Debt / Equity ratio of 0.
Current Ratio | 4.35 |
Quick Ratio | 4.35 |
Debt / Equity | 0 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $38,538.46 |
Profits Per Employee | $-3,064,153.85 |
Employee Count | 13 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 4K |
Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -46.4% in the
last 52 weeks. The beta is 1.37, so VYNE Therapeutics's
price volatility has been higher than the market average.
Beta | 1.37 |
52-Week Price Change | -46.4% |
50-Day Moving Average | 1.88 |
200-Day Moving Average | 2.26 |
Relative Strength Index (RSI) | 33.58 |
Average Volume (20 Days) | 160,229 |
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 501K
and earned -39.83M
in profits. Earnings per share was -0.93.
Revenue | 501K |
Gross Profit | 501K |
Operating Income | -43.64M |
Net Income | -39.83M |
EBITDA | -43.63M |
EBIT | -43.64M |
Earnings Per Share (EPS) | -0.93 |
Full Income Statement Balance Sheet
The company has 19.93M in cash and 99K in
debt, giving a net cash position of 19.83M.
Cash & Cash Equivalents | 19.93M |
Total Debt | 99K |
Net Cash | 19.83M |
Retained Earnings | -731.17M |
Total Assets | 66.91M |
Working Capital | 49.62M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -33.97M
and capital expenditures -117K, giving a free cash flow of -34.09M.
Operating Cash Flow | -33.97M |
Capital Expenditures | -117K |
Free Cash Flow | -34.09M |
FCF Per Share | -0.8 |
Full Cash Flow Statement Margins
Gross margin is 100%, with operating and profit margins of -8709.98% and -7950.9%.
Gross Margin | 100% |
Operating Margin | -8709.98% |
Pretax Margin | -7944.71% |
Profit Margin | -7950.9% |
EBITDA Margin | -8709.18% |
EBIT Margin | -8709.98% |
FCF Margin | -6804.19% |